<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100829">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01915459</url>
  </required_header>
  <id_info>
    <org_study_id>HG-13-01</org_study_id>
    <nct_id>NCT01915459</nct_id>
  </id_info>
  <brief_title>A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity</brief_title>
  <official_title>A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hugel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hugel</source>
  <oversight_info>
    <authority>South Korea: Ministry of Food and Drug Safety</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Botulax® compared to
      Botox® reducing upper limb muscle tone in post stroke patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The change in MAS(Modified Ashworth Scale) grade</measure>
    <time_frame>from baseline at week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in MAS (Modified Ashworth Scale) grade from baseline at week 4 for wrist flexor muscle tone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in muscle tone on MAS (Modified Ashworth Scale)for elbow, finger, and thumb flexor</measure>
    <time_frame>from baseline at week 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in muscle tone on MAS (Modified Ashworth Scale)for wrist, elbow, finger, and thumb flexor</measure>
    <time_frame>from baseline at week 8 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in DAS (Disability Assessment Scale) grade for the principal therapeutic target</measure>
    <time_frame>from baseline at week 4, 8, 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment evaluated by investigator</measure>
    <time_frame>at week 4, 8, 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment evaluated by patients</measure>
    <time_frame>at week 4, 8, 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in carer burden on Caregiver Burden Scale evaluated by caregiver</measure>
    <time_frame>from baseline at week 4, 8, 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Post Stroke Upper Limb Spasticity</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin type A(Botulax®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum toxin type A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum toxin type A(Botox®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Botulinum toxin type A</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botulinum toxin type A(Botulax®)</intervention_name>
    <description>IM, total dose of 360 Units at wrist flexor, elbow flexor, finger flexor, and thumb flexor based on muscle tone</description>
    <arm_group_label>Botulinum toxin type A(Botulax®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botulinum toxin type A(Botox®)</intervention_name>
    <arm_group_label>Botulinum toxin type A(Botox®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and Female patients, over 20 years of age

          2. Patients with a history of stroke more than 6weeks prior to enrollment

          3. Focal spasticity of wrist flexor measured with Modified Ashworth Scale (MAS) of 2 or
             greater at wrist and 1 or greater at least one of elbow flexor and finger flexor

          4. A minimum grade of 2 or greater on the Disability Assessment Scale(DAS) for targeted
             one functional disability item (i.e., hygiene, dressing, pain, or limb position)

          5. Patients who signed informed consent form, clearly understand the intent of the study
             and are able to comply with instructions to complete the entire study

        Exclusion Criteria:

          1. Patients with diagnosed neuromuscular disorders such as Lamber-Eaton syndrome,
             myasthenia gravis, or amyotrophic lateral sclerosis

          2. Patients with profound atrophy of the muscle in the target limb

          3. Patients with fixed joint/muscle contracture* in the target limb

               -  Defined as inability to passively move the joints

          4. Patients with history within 6 months or planned to have treatment with phenol or
             alcohol injection(chemodenervation) in the target limb

          5. Patients with history within 6 months or planned to have treatment with tendon
             lengthening in the target limb

          6. Patients who have concurrent treatment with an intrathecal baclofen

          7. Patients who had received Botulinum toxin injection within the past 3 months(for
             cosmetic purpose is allowed)

          8. Patients with concurrent or planned to take muscle relaxants and/or benzodiazepine
             medication (Allowed to participate if patient has consistently taken these medication
             from a month before screening visit and no changes in therapy are planned during the
             study)

          9. Patients with concurrent or planned to have physical, occupational, or splinting
             therapy (Allowed to participate if these therapies were consistently taken from a
             month before screening visit and no treatment changes are planned during the study

         10. Patients with a known allergy or sensitivity to the study medication or its
             components (Clostridium botulinum toxin type A, albumin, Sodium chloride, etc.)

         11. Patients who have participated in other clinical trials 1 month prior to this study

         12. Male and Female who are not willing to take any appropriate means of contraception or
             to have ascetic life at least 2 months after treatment

         13. Patients who are not eligible for this study at the discretion of the investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>YH Park</last_name>
    <phone>82-2-6900-9189</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Bundang</city>
        <state>Kyunggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Park</last_name>
      <phone>82-2-6900-9189</phone>
    </contact>
    <investigator>
      <last_name>Nam Jong Paik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Incheon St. Mary's hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Park</last_name>
      <phone>82-2-6900-9189</phone>
    </contact>
    <investigator>
      <last_name>Min Wook Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Park</last_name>
      <phone>82-2-6900-9189</phone>
    </contact>
    <investigator>
      <last_name>Min Ho Chun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chung Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Park</last_name>
      <phone>82-2-6900-9189</phone>
    </contact>
    <investigator>
      <last_name>Don Kyu Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Park</last_name>
      <phone>82-2-6900-9189</phone>
    </contact>
    <investigator>
      <last_name>Si Wook Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yoon Gil Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 2, 2013</lastchanged_date>
  <firstreceived_date>August 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
